drugset
drugset / Trial / NCT04465396

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

NCT04465396 ↗

Phase 1 Completed 64 enrolled Shire Takeda Development Center Americas, Inc. · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the bioavailability of teduglutide administered as a single subcutaneous (SC) fixed dose (depending upon participant weightband assignment) delivered by a syringe injection and the same fixed dose delivered by the pen injector in healthy participants.

Timeline

Start
2021-01-13
Primary completion
2021-08-20
Completion
2021-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Teduglutide Peptide 3 mg Subcutaneous
Subject Teduglutide Peptide 4 mg Subcutaneous

Indications

No indication recorded.